NovaBay Pharmaceuticals Total Current Liabilities Over Time
| NBY Stock | USD 0.68 0.04 5.56% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out NovaBay Pharmaceuticals Performance and NovaBay Pharmaceuticals Correlation. NovaBay |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NovaBay Pharmaceuticals. If investors know NovaBay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NovaBay Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (74.61) | Revenue Per Share 9.028 | Quarterly Revenue Growth (0.25) | Return On Assets (0.39) | Return On Equity (2.64) |
The market value of NovaBay Pharmaceuticals is measured differently than its book value, which is the value of NovaBay that is recorded on the company's balance sheet. Investors also form their own opinion of NovaBay Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is NovaBay Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NovaBay Pharmaceuticals' market value can be influenced by many factors that don't directly affect NovaBay Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NovaBay Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if NovaBay Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NovaBay Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Liabilities Analysis
Compare NovaBay Pharmaceuticals and related stocks such as Immix Biopharma, Cns Pharmaceuticals, and Effector Therapeutics Total Current Liabilities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMMX | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 5.3 M | 202 K | 1.3 M | 3.7 M | 2.4 M |
| CNSP | 220.7 K | 220.7 K | 220.7 K | 220.7 K | 220.7 K | 220.7 K | 220.7 K | 220.7 K | 1.2 M | 311 K | 1.9 M | 2.1 M | 4.9 M | 6.1 M | 6.4 M |
| SONN | 319.4 K | 3.6 M | 1.8 M | 5.5 M | 11.4 M | 16.2 M | 14.7 M | 2.9 M | 13 M | 4.7 M | 6.7 M | 8.2 M | 5.5 M | 13 M | 12.4 M |
| ZVSA | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 13.6 M | 8.2 M | 10.2 M | 10.9 M |
| ZURA | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 14.8 M | 20.3 M | 12.9 M |
| CYTO | 713.2 K | 713.2 K | 867.1 K | 16.6 M | 4.4 M | 6.2 M | 9 M | 10.4 M | 4.6 M | 2.3 M | 3 M | 4.9 M | 12.9 M | 888.9 K | 844.5 K |
| ENVB | 1000 K | 17.9 K | 25.7 K | 24.7 K | 9 K | 8.6 M | 12.7 M | 30.4 M | 14.7 M | 14.4 M | 681.2 K | 2.1 M | 4 M | 2.3 M | 3.7 M |
| PALI | 359.8 K | 2.4 M | 1.8 M | 5.9 M | 4 M | 6.5 M | 7.3 M | 1.5 M | 1.1 M | 1.2 M | 8.1 M | 2.5 M | 3 M | 2.6 M | 3.4 M |
| PHIO | 1.8 M | 1.8 M | 1.7 M | 2.1 M | 1.3 M | 2.3 M | 2.5 M | 2.3 M | 1.7 M | 1.9 M | 2.2 M | 3.1 M | 1.8 M | 1.6 M | 2.2 M |
NovaBay Pharmaceuticals and related stocks such as Immix Biopharma, Cns Pharmaceuticals, and Effector Therapeutics Total Current Liabilities description
Total Current Liabilities is an item on NovaBay Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of NovaBay Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.My Equities
My Current Equities and Potential Positions
| NovaBay Pharmaceuticals | NBY |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NYSE MKT Exchange |
USD 0.68
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.